Some searches may not work properly. We apologize for the inconvenience.
My bibliography Save this articleEconomic Evaluation of Companion Diagnostic Testing for EGFR Mutations and First-Line Targeted Therapy in Advanced Non-Small Cell Lung Cancer Patients in South Korea
Author
Abstract
Suggested Citation
DOI: 10.1371/journal.pone.0160155
Download full text from publisher
References listed on IDEAS
- Siying Wang & Liubao Peng & Jianhe Li & Xiaohui Zeng & Lihui Ouyang & Chongqing Tan & Qiong Lu, 2013. "A Trial-Based Cost-Effectiveness Analysis of Erlotinib Alone versus Platinum-Based Doublet Chemotherapy as First-Line Therapy for Eastern Asian Nonsquamous Non–Small-Cell Lung Cancer," PLOS ONE, Public Library of Science, vol. 8(3), pages 1-9, March.
- Katharina Schremser & Wolf Rogowski & Sigrid Adler-Reichel & Amanda Tufman & Rudolf Huber & Björn Stollenwerk, 2015. "Cost-Effectiveness of an Individualized First-Line Treatment Strategy Offering Erlotinib Based on EGFR Mutation Testing in Advanced Lung Adenocarcinoma Patients in Germany," PharmacoEconomics, Springer, vol. 33(11), pages 1215-1228, November.
Citations
Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
Cited by:
- Miriam Kasztura & Aude Richard & Nefti-Eboni Bempong & Dejan Loncar & Antoine Flahault, 2019. "Cost-effectiveness of precision medicine: a scoping review," International Journal of Public Health, Springer;Swiss School of Public Health (SSPH+), vol. 64(9), pages 1261-1271, December.
- Ling Pan & Peijia Ren & Zeshui Xu, 2018. "Therapeutic Schedule Evaluation for Brain-Metastasized Non-Small Cell Lung Cancer with A Probabilistic Linguistic ELECTRE II Method," IJERPH, MDPI, vol. 15(9), pages 1-23, August.
- Szu-Chun Yang & Wu-Wei Lai & Jason C Hsu & Wu-Chou Su & Jung-Der Wang, 2020. "Comparative effectiveness and cost-effectiveness of three first-line EGFR-tyrosine kinase inhibitors: Analysis of real-world data in a tertiary hospital in Taiwan," PLOS ONE, Public Library of Science, vol. 15(4), pages 1-13, April.
Most related items
These are the items that most often cite the same works as this one and are cited by the same works as this one.- Cuc Thi Thu Nguyen & Fabio Petrelli & Stefania Scuri & Binh Thanh Nguyen & Iolanda Grappasonni, 2019. "A systematic review of pharmacoeconomic evaluations of erlotinib in the first-line treatment of advanced non-small cell lung cancer," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 20(5), pages 763-777, July.
- Chunxiang Zhang & Hongmei Zhang & Jinning Shi & Dong Wang & Xiuwei Zhang & Jian Yang & Qizhi Zhai & Aixia Ma, 2016. "Trial-Based Cost-Utility Analysis of Icotinib versus Gefitinib as Second-Line Therapy for Advanced Non-Small Cell Lung Cancer in China," PLOS ONE, Public Library of Science, vol. 11(3), pages 1-10, March.
- Oscar Arrieta & Pablo Anaya & Vicente Morales-Oyarvide & Laura Alejandra Ramírez-Tirado & Ana C. Polanco, 2016. "Cost-effectiveness analysis of EGFR mutation testing in patients with non-small cell lung cancer (NSCLC) with gefitinib or carboplatin–paclitaxel," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 17(7), pages 855-863, September.
- Miriam Kasztura & Aude Richard & Nefti-Eboni Bempong & Dejan Loncar & Antoine Flahault, 2019. "Cost-effectiveness of precision medicine: a scoping review," International Journal of Public Health, Springer;Swiss School of Public Health (SSPH+), vol. 64(9), pages 1261-1271, December.
- Szu-Chun Yang & Wu-Wei Lai & Jason C Hsu & Wu-Chou Su & Jung-Der Wang, 2020. "Comparative effectiveness and cost-effectiveness of three first-line EGFR-tyrosine kinase inhibitors: Analysis of real-world data in a tertiary hospital in Taiwan," PLOS ONE, Public Library of Science, vol. 15(4), pages 1-13, April.
- Gursharan K. Sohi & Jordan Levy & Victoria Delibasic & Laura E. Davis & Alyson L. Mahar & Elmira Amirazodi & Craig C. Earle & Julie Hallet & Ahmed Hammad & Rajan Shah & Nicole Mittmann & Natalie G. Co, 2021. "The cost of chemotherapy administration: a systematic review and meta-analysis," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 22(4), pages 605-620, June.
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:plo:pone00:0160155. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: plosone (email available below). General contact details of provider: https://journals.plos.org/plosone/ .
Please note that corrections may take a couple of weeks to filter through the various RePEc services.